BioNTech (NASDAQ:BNTX) Posts Earnings Results, Misses Expectations By $1.34 EPS

BioNTech (NASDAQ:BNTX) announced its earnings results on Monday. The company reported ($3.36) earnings per share (EPS) for the quarter, missing the consensus estimate of ($2.02) by ($1.34), Briefing.com reports. The business had revenue of $128.70 million for the quarter, compared to analyst estimates of $134.98 million. BioNTech had a net margin of 4.01% and a return on equity of 0.55%. The company’s quarterly revenue was down 23.3% on a year-over-year basis. During the same period in the prior year, the company earned ($0.86) earnings per share. BioNTech updated its FY 2024 guidance to EPS.

BioNTech Stock Performance

Shares of NASDAQ:BNTX traded up $0.74 during trading on Wednesday, hitting $80.24. 405,162 shares of the stock traded hands, compared to its average volume of 699,299. The company has a quick ratio of 11.16, a current ratio of 11.38 and a debt-to-equity ratio of 0.01. The company has a fifty day moving average price of $87.45 and a two-hundred day moving average price of $90.50. BioNTech has a 52-week low of $76.53 and a 52-week high of $125.83. The company has a market cap of $19.08 billion, a price-to-earnings ratio of 159.00 and a beta of 0.23.

Wall Street Analyst Weigh In

BNTX has been the topic of several recent analyst reports. Hsbc Global Res upgraded shares of BioNTech from a “hold” rating to a “strong-buy” rating in a report on Friday, August 2nd. HC Wainwright reiterated a “buy” rating and set a $113.00 price objective on shares of BioNTech in a research note on Thursday, August 1st. Deutsche Bank Aktiengesellschaft raised BioNTech from a “hold” rating to a “buy” rating and set a $95.00 target price on the stock in a research report on Wednesday. BMO Capital Markets lowered their price target on BioNTech from $123.00 to $122.00 and set an “outperform” rating for the company in a research report on Tuesday, May 7th. Finally, Evercore ISI initiated coverage on BioNTech in a report on Tuesday, May 14th. They issued an “inline” rating and a $100.00 price objective on the stock. One equities research analyst has rated the stock with a sell rating, five have given a hold rating, five have issued a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, BioNTech presently has a consensus rating of “Moderate Buy” and a consensus price target of $109.00.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.